Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 3, Pages 1176-1181Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01470
Keywords
-
Categories
Funding
- College of Medicine, University of Florida
- National Center for Advancing Translational Sciences of the National Institutes of Health under University of Florida [TLITR001428, UL1TR001427]
- National Science Foundation [DMR-1332208]
- National Institute of General Medical Sciences, National Institutes of Health [GM-103485]
Ask authors/readers for more resources
Human carbonic anhydrase IX (CA IX) is upregulated in neoplastic tissues; as such, it is studied as a drug target for anticancer chemotherapy. Inhibition of CA IX has been shown to be therapeutically favorable in terms of reducing tumor growth. Previously, saccharin, a commonly used artificial sweetener, has been observed to selectively inhibit CA IX over other CA isoforms. In this study, X-ray crystallography showed acesulfame potassium (Ace K) binding directly to the catalytic zinc in CA IX (mimic) and through a bridging water in CA II. This modulation in binding is reflected in the binding constants, with Ace K inhibiting CA IX but not other CA isoforms. Hence, this study establishes the potential of Ace K (an FDA approved food additive) as a lead compound in the design and development of CA IX specific inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available